Estimation of the added value of 99mTc-HMPAO-labelled white blood cell scintigraphy for the diagnosis of infectious foci

Malherbe, Cécile; Dupont, Anne-Claire; Maïa, S.; Venel, Y.; Erra, B.; Santiago-Ribeiro, Maria-João; Arlicot, Nicolas

doi:10.23736/s1824-4785.17.02964-8

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since there are no other Tc-chelating agents available for WBC labelling, the only alternative consists in the use of antigranulocyte antibodies [ 22 – 24 ], leaving open doors to the study of new radiopharmaceuticals for bacterial imaging, although radiopharmaceuticals synthetized until now showed several limitations [ 25 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

Study of Binding Kinetics and Specificity of ^99mTc-SSS-Complex and ^99mTc-HMPAO to Blood Cells

Auletta

Iodice

Galli

et al. 2018

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Nuclear medicine offers several techniques and procedures to image infection, but radiolabelled autologous white blood cells (WBCs) are still the gold standard. These cells are usually labelled with 111In or 99mTc bound to a hydrophobic chelating agent that allows these isotopes to pass through the plasma membrane and enter in the cytoplasm. The most common compound in Europe is HMPAO that efficiently chelates 99mTc. However, up to 20–40% of the complex is released from the cells in the first few hours. The aim of this study was to radiolabel a new compound, (S3CPh)2 (S2CPh)-complex (SSS-complex) with 99mTc and compare its binding kinetics and specificity for WBC with HMPAO. The SSS-complex was labelled with 99mTc and analysed by iTLC and RP-HPLC. In vitro quality controls included a stability assay in serum and saline. Results showed a labelling efficiency of 95 ± 1.2% and 98 ± 1.4% for 99mTc-SSS-complex and 99mTc-HMPAO, respectively (p=ns). 99mTc-SSS-complex was stable in serum and in saline up to 24 h (94 ± 0.1%). Cell labelling experiments showed a higher incorporation of 99mTc-SSS-complex than 99mTc-HMPAO by granulocytes (62.6 ± 17.8% vs 40.5 ± 15%, p=0.05), lymphocytes (59.9 ± 22.2% vs 29.4 ± 13.5%; p=0.03), and platelets (44.4 ± 24% vs 20.5 ± 10.7%; p=ns), but the release of radiopharmaceutical from granulocytes at 1 h was lower for HMPAO than for SSS-complex (10.3 ± 1.9% vs 21.3 ± 1.8%; p=0.001). In conclusion, 99mTc-SSS-complex, although showing high labelling efficiency, radiochemical purity, and stability, is not a valid alternative to 99mTc-HMPAO, for example, in vivo white blood cells labelling because of high lymphocyte and platelet uptake and rapid washout from granulocytes.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of Binding Kinetics and Specificity of ^99mTc-SSS-Complex and ^99mTc-HMPAO to Blood Cells

Auletta

Iodice

Galli

et al. 2018

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…or mAb antigranulocytes a meta-analysis performed by annovazzi et al on 120 papers published from 1984 to 2005 on 4388 patients revealed that autologous leukocytes labeled with both 99m Tc and 111 in show higher diagnostic accuracy compared with monoclonal antibodies, barium studies, ultrasound and cT. 18 The sensitivity and specificity of study between 99m Tc-il2 and 99m Tc-hMPao granulocytes, in patients with inactive cd, the two radiopharmaceuticals, in most cases, accumulated in different areas, indicating that they can detect different types of inflammation, namely the lymphocytic infiltration in inflamed areas and the granulocytic infiltration in infected areas due to mucosal damage. 33 Both radiopharmaceuticals were characterized by high negative predictive values, but 99m Tc-il2 was also characterized by a better correlation with time to relapse. 34 The use of 99m Tcanti-TNFα has also been tested in CD for therapy decision-making and biological therapy follow-up, but the uptake of this radiopharmaceutical in the gut wall has been shown to be minimal and not to correlate with the response to therapy.…”

Section: Spect/ct Papers Using Radiolabeled Wbcmentioning

confidence: 97%

Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria

Catalano¹,

Maccioni²,

Lauri³

et al. 2018

Q J Nucl Med Mol Imaging

View full text Add to dashboard Cite

block as selectively as possible the pathological mechanisms responsible for the disease.New specific targeted therapies are being developed for several immune mediated diseases. Several clinical trials are being performed to assess the efficacy and safety of this approach. all of them, however, rely largely on the clinical assessment of the patients to evaluate the effect of treatment. an objective and reliable method to visualize directly the immune process underlying the individual disease would be valuable; specific diagnostic tests, furthermore, may allow the selection of patients to be treated. i nflammatory diseases are a heterogeneous class of diseases characterized by chronic inflammation of the target organ, often relapsing, invalidating and requiring life-long treatment. The so-called "aseptic chronic inflammatory diseases" include: autoimmune diseases, graft rejection, sarcoidosis, vasculitis, atherosclerosis and some degenerative diseases. in these patients, it is very important to try and achieve specific immunosuppression to extinguish the immune process with the aim of halting the disease, preventing or delaying complications and avoiding disease relapse, reducing to a minimum side effect by using specific immune therapies that

show abstract

“…As an alternative to WBC, we can also use MoAbs such as 99m Tc)-besilesomab (Scintimun ® ) to diagnose infections. These radiopharmaceuticals are directed against specific antigens expressed on the surface of granulocytes [3,4,5]. The lack of anatomical landmarks of planar images could represent a limiting factor of both radiolabelled WBC and MoAbs therefore the appeal to SPECT/CT is often mandatory in many specific clinical indications (for example in diabetic foot or vascular graft infection) in order to assess the exact location of the uptake and to evaluate the extent of the infective process.…”

Section: Introductionmentioning

confidence: 99%

Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology

Lauri

Auletta

Anzola

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Molecular nuclear medicine plays a pivotal role for diagnosis in a preclinical phase, in genetically susceptible patients, for radio-guided surgery, for disease relapse evaluation, and for therapy decision-making and follow-up. This is possible thanks to the development of new radiopharmaceuticals to target specific biomarkers of infection, inflammation and tumour immunology. Methods: In this review, we describe the use of specific radiopharmaceuticals for infectious and inflammatory diseases with the aim of fast and accurate diagnosis and treatment follow-up. Furthermore, we focus on specific oncological indications with an emphasis on tumour immunology and visualizing the tumour environment. Results: Molecular nuclear medicine imaging techniques get a foothold in the diagnosis of a variety of infectious and inflammatory diseases, such as bacterial and fungal infections, rheumatoid arthritis, and large vessel vasculitis, but also for treatment response in cancer immunotherapy. Conclusion: Several specific radiopharmaceuticals can be used to improve diagnosis and staging, but also for therapy decision-making and follow-up in infectious, inflammatory and oncological diseases where immune cells are involved. The identification of these cell subpopulations by nuclear medicine techniques would provide personalized medicine for these patients, avoiding side effects and improving therapeutic approaches.

show abstract

Estimation of the added value of 99mTc-HMPAO-labelled white blood cell scintigraphy for the diagnosis of infectious foci

Cited by 5 publications

References 0 publications

Study of Binding Kinetics and Specificity of ^99mTc-SSS-Complex and ^99mTc-HMPAO to Blood Cells

Study of Binding Kinetics and Specificity of ^99mTc-SSS-Complex and ^99mTc-HMPAO to Blood Cells

Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria

Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology

Contact Info

Product

Resources

About

Estimation of the added value of 99mTc-HMPAO-labelled white blood cell scintigraphy for the diagnosis of infectious foci

Cited by 5 publications

References 0 publications

Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells

Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells

Hybrid imaging in Crohn's disease: from SPECT/CT to PET/MR and new image interpretation criteria

Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology

Contact Info

Product

Resources

About

Study of Binding Kinetics and Specificity of ^99mTc-SSS-Complex and ^99mTc-HMPAO to Blood Cells

Study of Binding Kinetics and Specificity of ^99mTc-SSS-Complex and ^99mTc-HMPAO to Blood Cells